The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms

被引:43
作者
Bolt, J
Vo, QN
Kim, WJ
McWhorter, AJ
Thomson, J
Hagensee, ME
Friedlander, P
Brown, KD
Gilbert, J
机构
[1] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA
[2] Univ Florida, Coll Med, UF Shands Canc Ctr, Gainesville, FL 32610 USA
[3] LSU Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA USA
[4] LSU Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA USA
[5] LSU Hlth Sci Ctr, Dept Otolaryngol, New Orleans, LA USA
[6] LSU Hlth Sci Ctr, Sch Publ Hlth, New Orleans, LA USA
[7] LSU Hlth Sci Ctr, Dept Med, Infect Dis Sect, New Orleans, LA USA
[8] LSU Hlth Sci Ctr, Dept Med, Sect Hematol & Oncol, New Orleans, LA USA
关键词
HPV; SCCHN; ATM methylation; p53; mutation;
D O I
10.1016/j.oraloncology.2005.06.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The ATM/p53 pathway plays a critical role in maintenance of genome integrity and can be targeted for inactivation by a number of characterized mechanisms including somatic genetic/epigenetic alterations and expression of oncogenic viral proteins. Here, we examine a panel of 24 SCCHN tumors using various molecular approaches for the presence of human papillornavirus (HPV), mutations in the p53 gene and methylation of the ATM promoter. We observed that 30% of our SCCHN samples displayed the presence of HPV and all but one was HPV type 16. All HPV E6 gene-positive tumors exhibited E6 transcript expression. We observed 21% of the tumors harbored p53 mutations and 42% of tumors displayed ATM promoter methylation. The majority of tumors (71%) were positive for at least one of these events. These findings indicate that molecular events resulting in inactivation of the ATM/p53 pathway are common in SCCHN and can arise by a number of distinct mechanisms. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1013 / 1020
页数:8
相关论文
共 30 条
[11]   TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer [J].
Erber, R ;
Conradt, C ;
Homann, N ;
Enders, C ;
Finckh, M ;
Dietz, A ;
Weidauer, H ;
Bosch, FX .
ONCOGENE, 1998, 16 (13) :1671-1679
[12]   Genomic instability in head and neck cancer patients [J].
Friedlander, PL .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2001, 23 (08) :683-691
[13]   A GENOMIC SEQUENCING PROTOCOL THAT YIELDS A POSITIVE DISPLAY OF 5-METHYLCYTOSINE RESIDUES IN INDIVIDUAL DNA STRANDS [J].
FROMMER, M ;
MCDONALD, LE ;
MILLAR, DS ;
COLLIS, CM ;
WATT, F ;
GRIGG, GW ;
MOLLOY, PL ;
PAUL, CL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (05) :1827-1831
[14]   SIMULTANEOUS DETECTION AND TYPING OF GENITAL HUMAN PAPILLOMAVIRUS DNA USING THE POLYMERASE CHAIN-REACTION [J].
FUJINAGA, Y ;
SHIMADA, M ;
OKAZAWA, K ;
FUKUSHIMA, M ;
KATO, I ;
FUJINAGA, K .
JOURNAL OF GENERAL VIROLOGY, 1991, 72 :1039-1044
[15]   Evidence for a causal association between human papillomavirus and a subset of head and neck cancers [J].
Gillison, ML ;
Koch, WM ;
Capone, RB ;
Spafford, M ;
Westra, WH ;
Wu, L ;
Zahurak, ML ;
Daniel, RW ;
Viglione, M ;
Symer, DE ;
Shah, KV ;
Sidransky, D .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (09) :709-720
[16]   CELL-CYCLE CONTROL AND CANCER [J].
HARTWELL, LH ;
KASTAN, MB .
SCIENCE, 1994, 266 (5192) :1821-1828
[17]  
HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057
[18]  
Leonard DGB, 2002, CLIN CANCER RES, V8, P973
[19]   Human papillomavirus type 16 status in cervical carcinoma cell DNA assayed by multiplex PCR [J].
Lukaszuk, K ;
Liss, J ;
Wozniak, I ;
Emerich, J ;
Wójcikowski, C .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (02) :608-612
[20]  
MANOS MM, 1989, CANCER CEL, V7, P209